Literature DB >> 8193727

Evaluation of self-measured home vs. clinic intra-arterial blood pressure.

S E Kjeldsen1, A Moan, J Petrin, A B Weder, A J Zweifler, S Julius.   

Abstract

Home blood pressure (BP) monitoring is useful in the clinical management of patients with hypertension and the identification of those with "white-coat" hypertension; i.e. high readings in the clinic but normal BP at home. In the process of evaluating this technique, we compared self-measured home BP with intra-arterial BP. Healthy white men (n = 40) of 20-40 years of age and body weight below 95 kg were recruited by advertising in the local newspaper. Following a standardized procedure, performed within 2-4 weeks of a response to the advertisement, BP was measured by a physician at a clinic screening, by the subject at home (14 readings in 7 days) and finally in the clinic concomitantly intra-arterially and oscillometrically. The correlation coefficient for mean (M) home BP (r = 0.73) and oscillometric BP (r = 0.74) against intra-arterial BP were slightly higher than for screening BP (r = 0.65). However, in plots of the differences for individual MBP between the methods against the average of the methods, it appears that at levels of average MBP above 100 mmHg, screening BP overestimates the BP level, while this was not the case for home BP or oscillometric BP. Thus, by using intra-arterial measurement as standard of comparison, subject self-measured home BP is a reliable method of estimating blood pressure level in young men. Home BP measured shortly after screening and recruitment provides useful information of resting BP in subjects who potentially may have initial anxiety about BP measurement.

Entities:  

Mesh:

Year:  1993        PMID: 8193727     DOI: 10.3109/08037059309077523

Source DB:  PubMed          Journal:  Blood Press        ISSN: 0803-7051            Impact factor:   2.835


  1 in total

Review 1.  Importance of various methods of blood pressure measurement in clinical trials.

Authors:  P Palatini
Journal:  Curr Hypertens Rep       Date:  2000-08       Impact factor: 5.369

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.